CONCORD BIOTECH LIMITED Financial Ratios
CONCORDBIO · Healthcare · Current price ₹1,342.8
P/E ratio
37.7x
P/B ratio
6.8x
ROE
20.5%
ROCE
28.0%
Debt / Equity
0.00
Dividend yield
0.8%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 37.7x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 6.8x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 20.5% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 28.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.00 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with CONCORD BIOTECH LIMITED's latest numbers.
CONCORD BIOTECH LIMITED profitability
CONCORD BIOTECH LIMITED generates a return on equity of 20.5% and a return on capital employed of 28.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.00 and a P/E of 37.7x, CONCORD BIOTECH LIMITED is conservatively financed. Our overall business-quality score for the company is 4.6 / 10.
Understand the ratios
More on CONCORD BIOTECH LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.